US 11,674,125 B2
Glycoengineering
Robert M. Anthony, Arlington, MA (US); and Maya Kitaoka, Arlington, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Appl. No. 16/954,814
Filed by THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
PCT Filed Dec. 17, 2018, PCT No. PCT/US2018/066013
§ 371(c)(1), (2) Date Jun. 17, 2020,
PCT Pub. No. WO2019/126041, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/607,111, filed on Dec. 18, 2017.
Prior Publication US 2021/0207106 A1, Jul. 8, 2021
Int. Cl. C12N 9/10 (2006.01); A61P 37/06 (2006.01); A61P 19/02 (2006.01); A61P 13/12 (2006.01); A61K 38/00 (2006.01)
CPC C12N 9/1081 (2013.01) [A61P 13/12 (2018.01); A61P 19/02 (2018.01); A61P 37/06 (2018.01); C12N 9/1051 (2013.01); C12Y 204/01038 (2013.01); C12Y 204/99001 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)] 31 Claims
 
1. A fusion polypeptide comprising:
an antibody heavy chain CH2 region;
an antibody heavy chain CH3 region; and
a catalytic domain of a sialyltransferase, wherein the catalytic domain of the sialyltransferase catalyzes sialylation of a glycoprotein.